InstalabLoading...
InstalabLoading...
Most stool tests look at what is living in your gut. This one looks at what those microbes are doing to a specific bile acid your liver makes. Tauroursodeoxycholic acid sits at the intersection of liver chemistry, gut bacteria, and metabolism, and changes in its level have been tied to fatty liver disease, polycystic ovary syndrome, alcoholic liver injury, and even heart failure in people with metabolic disease.
Because this is an emerging research marker without standardized clinical cutpoints, a single number is less informative than a baseline you can track over time. Used alongside other gut and metabolic measurements, it can flag patterns worth investigating before they show up on conventional labs.
TUDCA (tauroursodeoxycholic acid) belongs to a family of cholesterol-derived molecules that your liver builds and your gut bacteria reshape. Liver cells make primary bile acids from cholesterol, then attach a small amino acid called taurine to them. The result, in the case of TUDCA, is a water-friendly bile acid that helps move fats through the digestive tract and signals through receptors involved in metabolism.
Once bile acids reach your intestine, your gut microbes get to work. Specific bacteria can strip the taurine off and convert one bile acid into another, which is part of why bile acid profiles vary so much between people. TUDCA is not a hormone, an enzyme, or a protein. It is a metabolite, meaning a small chemical product of your body's normal chemistry, and its level reflects the joint output of your liver and your microbiome.
TUDCA shows up in research across surprisingly different conditions, from liver disease to ovarian dysfunction to neurodegeneration. The thread running through all of them is endoplasmic reticulum stress (the strain that builds up when cells struggle to fold proteins correctly) and apoptosis (programmed cell death). TUDCA helps cells manage both. Tracking it gives you a glimpse into a chemistry pathway that touches several organ systems at once.
Among the disease links explored in human research, the connection to polycystic ovary syndrome (PCOS) is the most directly relevant for a stool test. Women with PCOS were found to have lower TUDCA in both stool and serum compared with women without the condition. The drop was tied to gut microbiome shifts, lower levels of an immune signaling molecule called IL-22, and worsening of the hormonal and metabolic features that define PCOS, including insulin resistance and ovarian dysfunction.
What this means for you: if you have PCOS or symptoms suggestive of it, a low TUDCA reading in stool may add a piece of biological context that hormonal testing alone does not provide, particularly around the gut-bile-immune axis.
TUDCA also moves with fatty liver disease, but the direction depends on context. In men with non-alcoholic fatty liver disease, serum TUDCA was elevated alongside other taurine-conjugated bile acids, a pattern researchers interpret as the body trying to compensate for fat-driven changes in bile chemistry. In a separate group of patients with metabolic dysfunction-associated fatty liver disease who also had heart failure with preserved ejection fraction, serum TUDCA and related ursodeoxycholic acid species were lower than in those without heart failure, suggesting a possible loss of protective bile acids.
Most of this evidence comes from blood-based bile acid profiling rather than stool, so the connection to a stool measurement is indirect. Still, both samples reflect the same underlying liver and microbial chemistry, and an unusual stool reading can be a starting point for a closer look.
In people with heavy drinking and alcoholic cirrhosis, taurine-conjugated bile acids in serum (the family TUDCA belongs to) rose dramatically, by up to 56-fold, compared with healthy controls. Researchers concluded that the overall pattern of taurine and glycine-conjugated bile acids could serve as non-invasive markers of how severe alcoholic cirrhosis is. This evidence is from blood, not stool, so the implication for a stool reading is suggestive rather than definitive.
In patients with intrahepatic cholangiocarcinoma (a cancer of the bile ducts inside the liver), the ratio of TUDCA in plasma compared to stool was altered alongside specific gut bacteria, and the combination helped distinguish this cancer from other liver diseases. This is one of the few clinical contexts where stool TUDCA itself is part of a biomarker panel, though the work is exploratory and there are no published sensitivity or specificity numbers for TUDCA on its own.
There are no standardized clinical reference ranges for stool TUDCA. The published research uses bile acid profiling on a study-by-study basis, with values reported in the context of healthy comparison groups rather than as universal targets. That makes a single absolute number less meaningful than where you sit relative to your own previous readings, or relative to a healthy reference cohort using the same lab and method.
When interpreting your result, focus on three questions. Is the value markedly different from what is typical for your age and sex in published cohorts? Is it changing over time? And does it line up with other findings, such as gut microbiome shifts, fatty liver markers, or PCOS-related hormones? A stool TUDCA reading on its own does not diagnose anything. It is a contextual data point.
Bile acids respond to what you eat, the bacteria currently dominating your gut, and your body's metabolic state on the day of collection. A single sample captures one snapshot. To know whether your level is genuinely high, low, or trending in a particular direction, you need at least two readings spaced apart, taken with consistent collection conditions.
A reasonable approach: get a baseline, repeat in 3 to 6 months if you are making targeted changes (a different diet, a new probiotic regimen, a microbiome-focused intervention), and then check at least annually if you are using this as part of ongoing health tracking. The pattern over time will tell you more than any single result.
A few practical factors can shift the reading without reflecting any real change in your underlying chemistry.
Because TUDCA is an exploratory marker without diagnostic cutpoints, the right next step depends on the rest of your picture rather than the number alone. If your reading is unusual and you have symptoms or risk factors for PCOS, fatty liver disease, or other metabolic conditions, treat the result as a prompt to look at the relevant companion tests. For PCOS, that means hormone panels including FSH, LH, and AMH. For fatty liver, liver enzymes, lipid panels, and metabolic markers like insulin and HbA1c (a measure of long-term blood sugar control). For broader gut chemistry, a full bile acid panel and a broader stool analysis can put TUDCA in context.
If your result is unusual but everything else looks normal, retest in a few months under similar conditions to see whether the pattern holds. A repeat reading in the same range is more informative than one outlier. If the pattern persists, a gastroenterologist or endocrinologist familiar with bile acid metabolism is the right specialist to involve.
Evidence-backed interventions that affect your Tauroursodeoxycholic Acid level
Tauroursodeoxycholic Acid is best interpreted alongside these tests.